Lantheus (LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of hear...
- Open
- 101.430
- High
- 101.430
- Low
- 100.740
- Prev. Close
- 100.960
- Volume
- 1.38M
- Turnover
- 139.36M
- Avg Price
- 100.972
- Bid/Ask Ratio
- -36.99%
- Amplitude
- 0.68%
- 52wk High
- 111.860
- Volume Ratio
- 1.72
- Turnover Ratio
- 2.35%
Lantheus Analyst Rating
View moreForecast & Rating
Sep 1, 2026Price forecast
$107.166.22%
Forecast & RatingHold
11analysts
- Strong buy18.18%
- Buy9.09%
- Hold72.73%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 hours ago
SkyOak Wealth LLC Reduces Stake in Lantheus Holdings, Inc. $LNTH
- MorningStar · Aug 29 at 12:03 PM
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
- Simplywall · Aug 25 at 09:30 AM
Is FDA Approval Of TAUKLARIFY Alzheimer’s Tau PET Agent Altering The Investment Case For Lantheus (LNTH)?
- Market Beat · Aug 23 at 09:52 AM
232,597 Shares in Lantheus Holdings, Inc. $LNTH Acquired by William Blair Investment Management LLC
- TradingView · Aug 19 at 08:20 AM
Lantheus Holdings, Inc. Stock 12‑Month Price Target Cut to $106.3, Implies 6% Upside
- Pharmaceutical Technology · Aug 17 at 10:47 AM
Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval
